ArticleDiscover oncology2026
Downregulation of GNPNAT1 impaired proliferation and correlates with immune infiltration in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glucosamine‑phosphate N‑acetyltransferase 1(GNPNAT1) is involved in metabolism in eukaryotic cells.Researches have reported that GNPNAT1 promoted the malignant behaviors of cancers.The role of GNPNAT1 in lung adenocarcinoma(LUAD) is little known.We analyzed the LUAD prognosis-associated genes using data from.The Cancer Genome Atlas(TCGA).And GNPNAT1 was identified.which was validated by quantitative real-time polymerase chain reaction, colony formation assay and MTT assay. UALCAN, The Human Protein Atlas(HPA), the Cancer Cell Line Encyclopedia(CCLE), TIMER, and TISIDB were used to analyze its relationship with clinical characteristics, co-expressed genes, immune infiltration, correlation with immunomodulators.GNPNAT1-associated gene, CD40LG was used to build a risk model to evaluate immunotherapy outcomes of patients with LUAD.GNPNAT1 was upregulated in LUAD both at mRNA and protein level in tumor tissues. Based on CD40LG, a risk model could predict the prognosis and immunotherapy outcome of LUAD.GNPNAT1 was an independent prognostic factor for LUAD.Our results have identified a prognosis-related gene that is useful to evaluate immunotherapy outcomes of LUAD patients.The signature may have crucial clinical significance in predicting survival prognosis, and immune infiltration based on GNPNAT1 gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.